Lakefront Biotherapeutics NV (LON:0JXZ)

Market Cap	1.46B +5.9%
Revenue (ttm)	911.38M +262.2%
Net Income	426.79M
EPS	6.48
Shares Out	n/a
PE Ratio	3.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	821
Open	25.12
Previous Close	25.46
Day's Range	24.94 - 25.86
52-Week Range	22.62 - 32.70
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About LON:0JXZ

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 558
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JXZ

Financial Performance

In 2025, LON:0JXZ's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error